<DOC>
	<DOC>NCT01791244</DOC>
	<brief_summary>This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmart™ device.</brief_summary>
	<brief_title>A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male or female, aged 18 or older A diagnosis of relapsingremitting multiple sclerosis according to the revised McDonald Criteria (2010) Treatment with Rebif® 22 or 44 mcg subcutaneously three times a week in accordance to the Summary of product characteristics Rebif® administered by the RebiSmart™ device Provided a signed informed consent form Has received any components, except for technical support, of MinSupport Plus prior to study entry Has difficulty reading and/or understanding Swedish Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude No access to computer Participation in another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
	<keyword>Rebif</keyword>
	<keyword>RebiSmart</keyword>
	<keyword>Patient support program</keyword>
</DOC>